42.20
-0.09(-0.21%)
Currency In USD
| Previous Close | 42.29 |
| Open | 42.42 |
| Day High | 42.99 |
| Day Low | 41.87 |
| 52-Week High | 51.61 |
| 52-Week Low | 14.2 |
| Volume | 366,939 |
| Average Volume | 742,900 |
| Market Cap | 2.67B |
| PE | -16.17 |
| EPS | -2.61 |
| Moving Average 50 Days | 45.28 |
| Moving Average 200 Days | 40.73 |
| Change | -0.09 |
If you invested $1000 in Vera Therapeutics, Inc. (VERA) since IPO date, it would be worth $3,669.57 as of January 03, 2025 at a share price of $42.2. Whereas If you bought $1000 worth of Vera Therapeutics, Inc. (VERA) shares 3 years ago, it would be worth $1,503.92 as of January 03, 2025 at a share price of $42.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
GlobeNewswire Inc.
Nov 18, 2024 1:00 PM GMT
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
GlobeNewswire Inc.
Nov 11, 2024 1:00 PM GMT
Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands the investigation of atacicept into multiple auto
Vera Therapeutics to Participate at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 08, 2024 1:00 PM GMT
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise